Association for Molecular Pathology
Annual Meeting & Expo

Asuragen: Breaking Barriers in Carrier Screening and Beyond: Unlocking Complex Variants with AmplideX^® Enrichment and Long-Read Sequencing

Wednesday, November 12th, 2025
12:00 PM - 12:50 PM EST
153B, Level 1

Dive into Asuragen’s cutting-edge AmplideX Nanopore Carrier Plus Kit (RUO), with a concise overview of its capabilities along with a preview of exciting upcoming product updates.

Gain valuable insights from a laboratory as they share their validation journey with an emphasis on workflow, data analysis software, and performance metrics.

Moderator:

Ninad Pendsé
Lead Product Manager, Genetics
Asuragen, a Bio-Techne Brand

Speakers:

Malia Deshotel, PhD
Scientist III, R&D Molecular Genetics
ARUP Laboratories

Elizabeth Barrie, PhD
Assistant Professor of Pathology, Associate Director of Molecular Diagnostics and Cytogenetics
Virginia Commonwealth University

Asuragen: ESR1  Testing and Monitoring in Metastatic Breast Cancer: A Paradigm Shift for Molecular Pathology Labs 

Wednesday, November 12th, 2025
1:00 PM - 1:50 PM EST
153B, Level 1

Join us for an engaging discussion with a top breast pathologist and a renowned breast oncologist on ESR1  mutation detection in advanced HR+/HER2- breast cancer. This interactive session will review the growing medical need for ESR1   mutation detection to inform treatment decisions. We will also cover pivotal clinical trials demonstrating the need for plasma-based ESR1  testing not only at progression but for monitoring while on therapy and discuss new approaches for optimizing test sensitivity in liquid biopsy specimens. Pathologists and lab professionals seeking personalized approaches for HR+/HER2 breast cancer management can't miss this informative session.

Moderator:

Jordan Laser, MD
Sr. Director, Clinical and Medical Affairs
Bio-Techne Diagnostics and Spatial Biology Segment

Panelists:

Deborah Dillon, MD
Assistant Professor, Pathology, Harvard Medical School
Staff Pathologist, Pathology, Brigham and Women's Hospital
Pathologist, Breast Oncology, Dana-Farber Cancer Institute
Director, Breast SPORE Biospecimen and Pathology Core, Dana-Farber Cancer Institute

Arielle Medford, MD
Breast Oncologist
Mass General Cancer Center

Roche: Purposeful Partnerships in Diagnostics: From Risk Reduction to Scalable Innovation 

Wednesday, November 12th, 2025
9:00 AM - 9:50 AM EST
151AB, Level 1

Successful diagnostic assay development and manufacturing rely on strong partnerships rooted in quality, reliability, and a spirit of collaboration. Join R&D, Operations, and Quality leaders from Asuragen for a practical panel discussion on selecting the right contract manufacturing and raw material partners. Learn how to define key selection criteria, engage suppliers early, and collaborate to reduce business and technical risk. Gain insights into aligning supplier capabilities with sustainability goals and ensuring consistent product quality. This session provides actionable guidance for assay developers looking to build resilient, compliant, and innovation-ready partnerships across the diagnostic lifecycle.

Moderator:

Hilary Graham, PhD, MA
Senior Director, Product Marketing Management
Bio-Techne Diagnostics Division

Panelists:

Jolene Osterberger
Global Account Manager
Roche Custom Biotech

Bernard Andruss, PhD
SVP & GM
Bio-Techne Diagnostics Division

Deepa Eveleigh, MS, MB(ASCP)CM
Director, Production-Custom & Lab Ops
Bio-Techne Diagnostics Division

John Milligan, PhD
Director, Product Development
Bio-Techne Diagnostics Division

Oxford Nanopore Technologies: Unlocking hidden genomic regions for rare disease research

Wednesday, November 12th, 2025
2:00 PM - 2:50 PM EST
156AB, Level 1

Long-Range PCR Meets Long-Read Sequencing to Resolve Challenging ACMG Tier 3 Carrier Screening Genes 
  
Asuragen’s recently launched Carrier Plus assay leverages amplification-based nanopore sequencing to enable high-confidence characterization of technically challenging genes included in the ACMG Tier 3 carrier screening recommendations in a single workflow. This presentation will highlight results from a global multisite evaluation of the assay’s performance and share preliminary data on expanded content designed to address additional complex regions and genes that remain difficult to resolve with conventional methods.

Speakers:

Brian Haynes, PhD
Senior Director, Research & Development
Bio-Techne Diagnostics Division

Scott Hickey, PhD
Senior Director, Commercial Applications
Oxford Nanopore Technologies